April 9, 2019 11:18 AM EDT

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

ENDPOINTS

→ China’s WuXi AppTec has recruited Frederick Hausheer as its chief medical officer. That gives him a global operational role with their clinical operations …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

ENDPOINTS

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

WuXi AppTec re­cruits new CMO; Em­bat­tled Alk­er­mes makes case for ex­pand­ed use of schiz­o­phre­nia drug Aris­ta­da

ENDPOINTS

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

WuXi AppTec recruits new CMO; Embattled Alkermes makes case for expanded use of schizophrenia drug Aristada

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?